Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Sun Pharma a trading play on dips, banks may face difficult June quarter: Dharmesh Kant
Dharmesh Kant, Head of Research at Chola Securities, said Sun Pharma’s all-cash acquisition of Organon could improve return ratios and support valuations, but may bring overall revenue growth down to single digits. He sees a trading opportunity in Sun Pharma on price dips. On banking, he said Q1 could be difficult as provisioning picks up, which may weigh on profitability even as asset quality and margins remain stable. Disclaimer: The views and tips expressed by investment experts on CNBCTV18.com are their own, not of the website or its management. CNBCTV18.com advises users to check with certified experts before taking any investment decisions.
Tata Elxsi shares fall over 4% after weak Q4. Motilal Oswal, HDFC Securities cut target price
In the wake of Tata Elxsi's Q4FY26 performance, shares tumbled by 4%. While the company boasted a healthy 28% increase in net profit paired with a 9% revenue growth, the market reacted cautiously. Analysts are divided; some predict subdued growth spurred by delayed contracts, whereas others identify untapped opportunities in niche markets. The stock’s current valuation continues to spark debate.